Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The relationship between the prescribed dose of drugs during continuing (maintenance) therapy, the degree of marrow suppression caused, and subsequent event-free survival was examined in a cohort of 740 children with lymphoblastic leukaemia treated on MRC UKALL X. Girls, younger children, and patients who had received intensification treatment, were prescribed lower doses of mercaptopurine, became neutropenic more readily, and had more interruptions of treatment. Children who had one or more episodes of neutropenia with a count of <0.5 x 10(9)/l had a better prognosis than those who never became neutropenic. We conclude that early intensification treatment influences the probability of neutropenia during continuing treatment and that patients exhibiting myelosuppression during this phase of treatment have a better chance of prolonged remission.

Type

Journal article

Journal

Br J Haematol

Publication Date

09/1997

Volume

98

Pages

945 - 951

Keywords

Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Infant, Infant, Newborn, Male, Neutropenia, Precursor Cell Lymphoblastic Leukemia-Lymphoma